Brief: Olema Oncology Announces Clinical Trial Collaboration And Supply Agreement With Bayer To Evaluate Op-3136 In Combination With Nubeqa® (Darolutamide) In Metastatic Castration-Resistant Prostate Cancer
26/05/2026 12:10
May 26 (Reuters) - Olema Pharmaceuticals Inc OLMA.O: OLEMA ONCOLOGY ANNOUNCES CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH BAYER TO EVALUATE OP-3136 IN COMBINATION WITH NUBEQA® (DAROLUTAMIDE) IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER OLEMA PHARMACEUTICALS INC - ANNOUNCES CLINICAL TRIAL COLLABORATION WITH BAYER FOR OP-3,136 AND DAROLUTAMIDE IN MCRPC OLEMA PHARMACEUTICALS INC - STUDY TO EVALUATE OP-3,136 AND DAROLUTAMIDE IN 36 PATIENTS, INITIATION EXPECTED IN H2 2026 Source text: ID:nGNX4YnNbN Further company coverage: OLMA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Olema Oncology
See all newsBrief: Olema Pharmaceuticals Changes Corporate Name To Olema Oncology, Effective Today
Olema Pharmaceuticals, Inc. reports results for the quarter ended September 30 - Earnings Summary
Olema Pharma Q3 net loss widens on higher costs
Brief: Olema Pharmaceuticals Q3 Net Income USD -73.599 Million
Olema Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary